Clinical Trial Update: A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 [Phase 1]

View source ↗

Summary

A Phase Ia/Ib first-in-human study of ADEL-Y01 for Alzheimer's disease has been suspended, evaluating safety, tolerability, pharmacokinetics, and preliminary cl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ADEL-Y01

Snippet

Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc. | Conditions: Alzheimer Disease | Phase 1 | Status: SUSPENDED